SignalSilence ® p53 siRNA II from Cell Signaling Technology

Product Specs
ItemSignalSilence ® p53 siRNA II
CompanyCell Signaling Technology
Price $369.00 Inquire
Catalog Number6562S
Quantity300 µl
Targetp53
NCBI Gene AliasesBCC7, BMFS5, LFS1, P53, TRP53
NCBI Full Gene Nametumor protein p53
Research AreaCell Cycle / Checkpoint Control
ReactivityH
ApplicationssiRNA
TypesiRNA

Add to Compare List

Cell Signaling Technology

3 Trask Lane

Danvers, Massachusetts 01923

United States

Phone: 877-616-CELL
Phone: 978-867-2388
Fax: 866-432-6112
Fax: 978-867-2488

Company Profile

Website: http://www.cellsignal.com/

Website: Technical Support

(1) Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinomaeLifeJune 9, 2020Hastings JF, Gonzalez Rajal A, Latham SL, Han JZ, McCloy RA, O'Donnell YE, Phimmachanh M, Murphy AD, Nagrial A, Daneshvar D, et al.,Cell Signaling Technology,#6231, Transfected construct (human),SignalSilence p53 siRNA II,Cell Signaling Technology,#6562, Sequenced-based reagent,SignalSilence Control siRNA (Unconjugated),Cell Signaling Technology,#6568,

(2) Tanshinone IIA reverses EGF‑ and TGF‑β1‑mediated epithelial‑mesenchymal transition in HepG2 cells via the PI3K/Akt/ERK signaling pathwayOncology LettersNovember 1, 2019Longkai Zhang, Weibin Lin, Xiaodan Chen, Gang Wei, Hailong Zhu, Shangping Xingsecondary antibodies conjugated to fluorescein isothiocyanate (cat. 6556 ONCOLOGY LETTERS 18: 6554-6562, 2019 no. 4412; 1:1,000; Cell Signaling Technology, Inc.) for 1 h at room temperature, and the nuclei

(3) Reactive oxygen species stress increases accumulation of tyrosyl-DNA phsosphodiesterase 1 within mitochondriaScientific ReportsDecember 1, 2018Hok Khim Fam, Kunho Choi, Lauren Fougner, Chinten James Lim, Cornelius F. Boerkoeltransfected with ERK1 siRNA (Thermo Scientific/Dharmacon; L-003592-00-0005), p38 siRNA (Cell Signaling; 6562 S) or Tim23 siRNA (Thermo Scientific/Dharmacon; L-190121-00-0005). Rho-zero MEFs were transfected with

(4) The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasisNature communicationsNovember 21, 2017Fusella F, Seclì L, Busso E, Krepelova A, Moiso E, Rocca S, Conti L, Annaratone L, Rubinetto C, Mello-Grand M, et al.

(5) Mechanisms of the anti-tumor activity of Methyl 2-(-5-fluoro-2-hydroxyphenyl)-1 H-benzo[d]imidazole-5-carboxylate against breast cancer in vitro and in vivoOncotargetApril 25, 2017Hasanpourghadi M, Pandurangan AK, Karthikeyan C, Trivedi P, Mustafa MR.

(6) Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progressionJournal of Clinical InvestigationMarch 1, 2013Rachana Patel et al.were selected using geneticin (500 μg/ml; Gibco, Invitrogen). The PTEN siRNA (6251) and p53 siRNA (6562) were obtained from Cell Signaling. The PTEN expression construct (EGFPPTEN) was generated by cloning

(7) Properties and nature of Be starsAstronomy & AstrophysicsJanuary 1, 2012J. NemravovÃ¡, P. Harmanec, P. KoubskÃ½, A. Miroshnichenko, S. Yang, M. Å lechta, C. Buil, D. KorÄÃ¡kovÃ¡, V. Votrubaof spectra Ond Rit OHP DAO OHP/Cst 4 55398.4531 3 55100.3285 54533.2727 2 53745.5116 53258.5126 1 52730.5717 0 -1 6532 6542 6552 6562 6572 6582 6592 wavelength[A] Fig. 1. Recent evolution of the Hα line profile. Mid-exposure times

(8) Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesisOncogeneOctober 19, 2006H Takada, I Imoto, H Tsuda, Y Nakanishi, C Sakakura, S Mitsufuji, S Hirohashi, J Inazawavery-low-density lipoprotein receptor. Oncogene Silencing of VLDLR in gastric cancer H Takada et al 6562 of VLDLR-type I/II protein in transiently transfected cells were conﬁrmed 36 h after transfection by Western blot

Be the First to Write a Review!